FIELD: laboratory diagnostics.
SUBSTANCE: invention can be used for enzyme immunoassay quantitative determination of virus-neutralizing antibodies to the receptor-binding domain — RBD of surface glycoprotein S of the SARS-CoV-2 virus in human serum or blood plasma and laboratory animals. The invention is a set of reagents for enzyme immunoassay quantitative determination of virus-neutralizing antibodies to SARS-CoV-2, which implements a two-stage "competitive" variant of enzyme-linked immunosorbent assay.
EFFECT: obtaining a reagent kit for enzyme immunoassay quantitative determination of virus-neutralizing antibodies to SARS-CoV-2.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
| Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof | 2020 |
|
RU2723008C1 |
| THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
| STRAIN OF HCOV-19/RUSSIA/OMSK-202118-1707/2020 OF SARS-COV-2 CORONAVIRUS, IMMUNOSORBENT CONTAINING PURIFIED WHOLE VIRION ANTIGEN OBTAINED ON BASIS OF SPECIFIED STRAIN AND ISA TEST SYSTEM FOR DETECTING ANTIBODIES OF CLASSES M, G AND A TO SARS CORONAVIRUS-COV-2 USING SPECIFIED IMMUNOSORBENT | 2021 |
|
RU2752862C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| TEST SYSTEM AND METHOD FOR DIFFERENTIAL DETECTION OF ANTIBODIES TO SARS-COV-2 | 2021 |
|
RU2754340C1 |
